Small-cap penny stock below ₹5 hits upper circuit after announcement of stock split move
Small-cap penny stock Murae Organisor hit 5% upper circuit limit as the board is expected to declare a stock split. The company has revealed that it will deliberate on a significant corporate decision that reflects its continuous dedication to enhancing shareholder value. The board of the company will convene on April 24, 2025, to discuss the possibility of a stock split.
'To consider and approve the proposal to Sub- Division /Split of the Equity Shares of the Company in such manner as may be determined by the Board of Directors and subject to approval of the Shareholders and such authorities as may be required under Section 61 of the Companies Act, 2013. and Sebi Regulations 2015,' said the company in an filing.
According to data from Trendlyne, Murae Organisor has executed a share split once since December 16, 2021. The company last reduced the face value of its shares from ₹ 10 to ₹ 2 in 2021. The share has been trading on an ex-split basis since December 16, 2021.
Murae Organisor is dedicated to fostering innovation and excellence in various sectors, such as agriculture, cattle feed, fertilizers, chemicals, and gold. With a strong emphasis on quality and sustainability, the Company strives to provide effective solutions that promote industry advancement and meet changing requirements.
The firm recorded a remarkable 384.3% increase in revenue from the previous quarter, with total operational revenue rising to ₹ 281.04 crore in Q3 FY25, up from ₹ 58.00 crore in the prior quarter. This significant revenue growth reflects strong market demand, effective execution of new contracts, and a growing distribution network. The company's profitability has also experienced a notable rise, with net profit climbing 344.3% to ₹ 4.01 crore, in contrast to ₹ 0.90 crore in Q2 FY24.
Murae Organisor share price reached its upper circuit on both April 17 and April 16. During the trading session yesterday, the volume of Murae Organisor's shares surged by over 1.09 times. Murae Organisor share price today opened at an intraday low of ₹ 1.43 apiece on the BSE, the stock touched an intraday high of ₹ 1.44 per share.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
37 minutes ago
- Time of India
BSE shares today: Stock prices plunge 4% post being placed under ASM framework - here's what's happened
BSE share price has increased by 116.6% over three months and 225.6% in the past year. (AI image) BSE share price plunges: BSE Ltd shares declined 4% to Rs 2,885.20 on the NSE on Wednesday after the exchange placed the stock under Additional Surveillance Measure (ASM) framework, leading to wariness amongst investors. BSE share price has increased by 116.6% over three months and 225.6% in the past year. BSE shares have risen approximately 32% in the previous month and 58.5% over six months. The substantial appreciation in share value likely prompted regulatory attention, as exchanges commonly implement ASM measures to address excessive volatility and speculation. The ASM framework serves as a regulatory instrument utilised by exchanges to supervise and regulate unusual price fluctuations. Securities under ASM face stricter oversight and trading constraints, including elevated margin requirements and restrictions on intraday transactions, aimed at protecting investors and ensuring market stability. The inclusion follows a notable increase in BSE's share price and trading volume. Stock exchanges generally incorporate shares into the ASM category when they observe substantial price movements unsupported by fundamental factors or unusual trading patterns, according to an ET report. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 임플란트, 지금 시작하세요 [자세히 보기] 임플란트 더 알아보기 Undo BSE shares currently maintain positions above most crucial simple moving averages (SMAs), specifically the 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day markers. The stock has, however, dipped beneath the 5-day SMA, indicating recent softening in performance, the report said. The RSI reading of 80.9 exceeds the overbought level of 70, suggesting a potential downward correction. Nevertheless, the MACD maintains a strong positive value of 208.2, positioned above its centre and signal lines, which confirms ongoing bullish sentiment despite the midweek decline. BSE has demonstrated remarkable financial performance, with its recent stock surge supported by exceptional fourth-quarter results. The exchange recorded a substantial 362% year-on-year increase in net profit, reaching Rs 494 crore during January-March 2025. Operational revenue witnessed a 75% year-on-year growth to Rs 847 crore. The operating EBITDA, inclusive of core Settlement Guarantee Fund (SGF) contributions, showed remarkable improvement, rising to Rs 594 crore from Rs 95.7 crore in the previous year. The EBITDA margins showed substantial improvement, reaching 70%. Transaction charges, which constitute a significant revenue source tied to trading volumes, increased by 112% year-on-year to Rs 612 crore, compared to Rs 288 crore in the corresponding period. Investment income improved to Rs 70 crore from Rs 55.2 crore in Q3 FY25, whilst treasury income decreased to Rs 44.3 crore from Rs 58 crore the previous year. The exchange's board announced a combined dividend of Rs 23 per share, comprising Rs 5 as a special dividend commemorating BSE's 150th anniversary and Rs 18 as the standard dividend. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
&w=3840&q=100)
Business Standard
42 minutes ago
- Business Standard
Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years
Wockhardt share price today: Shares of pharmaceutical company Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17 per cent on the BSE in Wednesday's intra-day trade amid heavy volumes on healthy business outlook. The stock price of this smallcap pharmaceutical company surpassed its previous high of ₹1,678.60, which it had touched on February 6, 2025. In the past one month, Wockhardt has outperformed the market by surging 47 per cent, as compared to 0.3 per cent rise in the BSE Sensex. Further, in the past year, the stock zoomed 206 per cent, as against 8 per cent gain in the benchmark index. The stock price of Wockhardt has skyrocketed 956 per cent from level of ₹171.45 on the BSE. At 12:36 PM; the stock was quoting 16 per cent higher at ₹1,802.40, as against 0.33 per cent gain in the BSE Sensex. The average trading volumes on the counter jumped three-fold. A combined 4.34 million shares have changed hands on the NSE and BSE. Rekha Jhunjhunwala held over 1 per cent holding in Wockhardt Ace investor Rekha Jhunjhunwala held 2.84 million shares representing 1.75 per cent stake in Wockhardt at the end of March 31, 2025, the shareholding pattern data shows. Strong FY25 results Wockhardt had reported a strong operational performance with 67 per cent year-on-year (Y-o-Y) growth in earnings before interest, taxes, depreciation, and amortisation (Ebitda) at ₹418 crore for the financial year 2024-25 (FY25) compared to ₹251 crore in the previous year (FY24). Ebitda margin improved to 13.8 per cent, from 8.7 per cent. Revenue, however, grew 5 per cent Y-o-Y to ₹3,033 crore in FY25, compared to ₹2,879 crore in FY24. For FY25, the company said its net loss stood at ₹57 crore as compared to ₹472 crore in the year-ago period. Zaynich: Planned for filing in USA by August 2025 Following the completion of the Global, pivotal, registration-enabling, Phase III study in hospitalised complicated urinary tract infection (cUTI) patients, Wockhardt's Zaynich has demonstrated the highest-ever efficacy achieving a clinical cure rate of 96.8 per cent. Wockhardt, while announcing Q4 results on May 29, 2025, said that this study is NDA-enabling, based on which marketing authorisation applications will be made to global health authorities including India, US, EMA and MHRA. For India, the Drug Controller General of India (DCGI) filing for commercial approval was submitted on March 31, 2025. In parallel, preparations for the US New Drug Application (NDA) filings are progressing, marked by the successful completion of a pre-NDA meeting with the US Food and Drug Administration (FDA). Filing in the USA is expected by August 2025, the company said. Meanwhile, Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug would have an addressable market of $7 billion in the US and Europe, besides a ₹17,000 crore opportunity in India, taking the total opportunity to $9 billion. The company is expecting to get a nod from the DCGI soon. It hopes for a launch in the second half of this financial year. In an investor presentation, Wockhardt said that it had completed the pre-ANDA meeting with the US Food and Drug Administration (USFDA) in May and is filing with the regulator in Q2FY26, expecting a potential launch in the financial year 2026-27 (FY27). It aims to file for approval in the European Union (EU) and emerging markets in H2FY26. Apart from Zaynich, Wockhardt is pinning its hopes on other drugs in its antibiotic portfolio (like Miqnaf or Nafithromycin), and its biotechnology portfolio including insulins. Miqnaf is targeting a ₹10,800 crore market opportunity in India with over 96 million potential prescriptions. About Wockhardt Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on the unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'. It has a comprehensive Drug Discovery team and clinical organisation. Wockhardt has a significant presence in the USA, Europe and India, with 77 per cent of its global revenues coming from international businesses.
Mint
an hour ago
- Mint
Vedanta subsidiary Hindustan Zinc declares ₹10 per share interim dividend. Details here
Dividend stocks: Hindustan Zinc, a subsidiary of metals and mining major Vedanta, on Wednesday, June 11, announced an interim dividend of ₹ 10 per share of ₹ 2 each, amounting to a 500% payout considering the face value. '… We wish to inform you that the Board of Directors of the Company through a resolution passed by circulation on Wednesday, June 11, 2025, at 12:56 pm, have approved the first Interim Dividend of Rs. 10 per equity share i.e. 500% on face value of Rs. 2/- per equity share for the Financial Year 2025-26,' Hindustan Zinc said in a filing to the exchanges. Hindustan Zinc, in an earlier update, has already communicated the record date for the purpose of the interim dividend. The company had fixed Tuesday, June 17, 2025, as the record date to identify shareholders eligible to receive the first interim dividend, the company said. It added that the dividend shall be duly paid within the stipulated timelines as prescribed under law.
